Canaccord analyst Richard Close lowered the firm’s price target on Teladoc (TDOC) to $14 from $17 and keeps a Buy rating on the shares. The firm recognizes this could certainly be a value trap, and fully understand that it will take time for Teladoc’s CEO Chuck Divita to put his stamp on the operations, but it is worth highlighting that Teladoc continues to expand its reach.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TDOC:
- Teladoc price target raised to $11 from $10 at Cantor Fitzgerald
- Teladoc price target lowered to $8 from $9 at TD Cowen
- Teladoc price target raised to $12 from $10 at Barclays
- Teladoc Health Reports Q3 2024 Financial Results
- Closing Bell Movers: Microsoft, Meta both down about 3% despite earnings beats